| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/13/2006 | US7060700 Amide derivatives useful as inhibitors of the production of cytokines |
| 06/13/2006 | US7060699 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 06/13/2006 | US7060685 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries |
| 06/13/2006 | US7060683 for treatment of neurodegeneration, stroke, Alzheimer's, amyotrophy, motor neuron damage, acute central nervous system injury, muscular dystrophy, bone resorption, platelet aggregation, cataracts and inflammation |
| 06/13/2006 | US7060681 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 06/13/2006 | US7060675 Administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes |
| 06/13/2006 | US7060305 extracts contain higher concentration of isoflavones; used to treat erectile dysfunction or malfunction |
| 06/13/2006 | US7060302 Metal-containing compositions, preparations and uses |
| 06/13/2006 | US7060285 Dispersions for the formulation of slightly or poorly soluble agents |
| 06/13/2006 | US7060259 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 06/13/2006 | CA2433288C Process for making amlodipine maleate |
| 06/13/2006 | CA2268954C Oxadiazoles, processes for their preparation and their use as medicaments |
| 06/08/2006 | WO2006060765A2 Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals |
| 06/08/2006 | WO2006060127A2 COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
| 06/08/2006 | WO2006060122A2 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| 06/08/2006 | WO2006059945A1 Novel compounds |
| 06/08/2006 | WO2006059801A1 7-membered ring compound, process for producing the same, and medicinal use thereof |
| 06/08/2006 | WO2006059778A1 Substituted pyridone derivative |
| 06/08/2006 | WO2006059744A1 ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ |
| 06/08/2006 | WO2006059507A1 11β-HSD1 ANTISENSE COMPOUND |
| 06/08/2006 | WO2006059423A1 Medicine for treatment of disease caused by hyperstimulatory cytotoxicity and therapeutic method |
| 06/08/2006 | WO2006059329A1 Platelet-derived microparticles for therapy |
| 06/08/2006 | WO2006059217A1 Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| 06/08/2006 | WO2006059165A1 Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase |
| 06/08/2006 | WO2006058905A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY |
| 06/08/2006 | WO2006058748A1 Use of megestrol acetate for improving heart function and the treatment of heart insufficiency |
| 06/08/2006 | WO2006058483A1 USE OF 3, 4’,5-TRIHYDROXY-STILBENE-3- β-D-GLUCOSIDE IN PREPARATION OF MEDICINES FOR TREATING AND/OR PREVENTING ISCHEMIC HEART DISEASE |
| 06/08/2006 | WO2006058411A1 Pyridoxal-5´-phosphate and related compounds in combination with therapeutic cadiovascular compounds for treating angina. |
| 06/08/2006 | WO2006044602A9 Diphenyl substituted alkanes as flap inhiibitors |
| 06/08/2006 | WO2006040451A3 Novel 9h-pyrido[2,3-b]indole derivatives serving as cdk and gsk3 inhibitors, method for the preparation thereof, and the pharmaceutical compositions containing such compounds |
| 06/08/2006 | WO2006037869A3 Fluorophosphonocinnamic compounds, synthesis and uses for treating disorders caused by oxidative stress |
| 06/08/2006 | WO2006035319A3 Methods of using chimeric coiled-coil molecule |
| 06/08/2006 | WO2006021656A3 Aminopiperidine derivatives, preparation thereof and use thereof as melanocortin receptor agonists |
| 06/08/2006 | WO2005123721A3 Amorphous and polymorphic forms of candesartan cilexetil |
| 06/08/2006 | WO2005105787A8 Rapid and robust 3d/3d registration technique |
| 06/08/2006 | WO2005062824A8 Anti-hypercholesterolemic compounds |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |
| 06/08/2006 | US20060122392 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient |
| 06/08/2006 | US20060122387 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| 06/08/2006 | US20060122374 Albumin-fused anti-angiogenesis peptides |
| 06/08/2006 | US20060122370 Specific binding agents of human angiopoietin-2 |
| 06/08/2006 | US20060122273 Use for deferiprone |
| 06/08/2006 | US20060122264 Stem cell invasion inhibitor |
| 06/08/2006 | US20060122249 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 06/08/2006 | US20060122244 Hypoglycemic agents; antidiabetic agentys; side effect reduction; cardiovascular disorders; anticancer agents |
| 06/08/2006 | US20060122242 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/08/2006 | US20060122239 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 06/08/2006 | US20060122234 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 06/08/2006 | US20060122221 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 06/08/2006 | US20060122215 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity |
| 06/08/2006 | US20060122207 Imidazol derivatives as Raf kinase inhibitors |
| 06/08/2006 | US20060122188 Anticoagulants; 2-[1S-(4-(ethoxycarbonyl)piperazin-1-yl)carbonyl-3-carboxypropyl]aminocarbonyl-4-(2-methylthiazol-4-yl)methoxyquinoline; antithrombotic agents in the treatment and prevention of thrombosis |
| 06/08/2006 | US20060122176 such as 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione, used for the treatment and/or prophylaxis of autoimmune, cardiovascular or neurodegenerative disorders, inflammatory or kidney diseases, bacterial or viral infections, platelet aggregation, cancer, transplant rejection or lung injuries |
| 06/08/2006 | US20060122110 Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system |
| 06/08/2006 | US20060121529 CpG receptor (CpG-R) and methods relating thereto |
| 06/08/2006 | US20060121514 Prostacyclin-stimulating Factor-2 |
| 06/08/2006 | US20060121180 Using electrochemical solution containing metal compound and bioactive materials; contacting substrate |
| 06/08/2006 | US20060121136 Hypotensive agent and method for producing same |
| 06/08/2006 | US20060121129 Dietary supplement |
| 06/08/2006 | US20060121117 Anti-angiogenic compositions and methods of use |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121025 VEGF-related protein |
| 06/08/2006 | US20060121022 an antibody against protein C or activated protein C (aPC) comprising the heavy chain and light chain complementarity determining regions; used for suppressing activation of the blood coagulation system and antiinflammatory activity; therapy for diseases such as thrombosis and sepsis |
| 06/08/2006 | US20060121015 Probiotic bifidobacterium strains |
| 06/08/2006 | US20060120985 Novel ampiphilic derivatives of alpha-c-phenyl-n-tert-butyl nitrone |
| 06/08/2006 | DE20122582U1 Zubereitung für Restenoseprophylaxe Preparation for prophylaxis of restenosis |
| 06/08/2006 | CA2589638A1 7-membered ring compound and method of production and pharmaceutical application thereof |
| 06/08/2006 | CA2588980A1 Vasopressin-binding l-nucleic acid |
| 06/08/2006 | CA2588949A1 Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| 06/08/2006 | CA2588947A1 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| 06/08/2006 | CA2588867A1 Substituted pyridone derivative |
| 06/08/2006 | CA2588517A1 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family |
| 06/08/2006 | CA2588453A1 Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals |
| 06/08/2006 | CA2580970A1 Pyridoxal-5´-phosphate and related compounds in combination with therapeutic cardiovascular compounds for treating angina. |
| 06/07/2006 | EP1666880A1 Screening method |
| 06/07/2006 | EP1666480A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. |
| 06/07/2006 | EP1666479A1 Crystal of heterocyclic compound |
| 06/07/2006 | EP1666473A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 06/07/2006 | EP1666472A1 Phenylacetic acid derivative, process for producing the same, and use |
| 06/07/2006 | EP1666469A1 Plasminogen activator inhibitor-1 inhibitor |
| 06/07/2006 | EP1666460A1 Preventive for cerebral stroke recurrence |
| 06/07/2006 | EP1666459A2 Aminocyclohexyl ether compounds and uses thereof |
| 06/07/2006 | EP1666445A1 Reduced coenzyme q sb 10 /sb crystal excelling in stability and composition containing reduced coenzyme q10 crystal |
| 06/07/2006 | EP1666092A2 Drug combination comprising a fatty acid and a uridine compound. |
| 06/07/2006 | EP1666071A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666070A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666068A1 Remedy for eye diseases accompanied by optic nerve injuries |
| 06/07/2006 | EP1666067A1 Drug containing chymase inhibitor as the active ingredient |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666042A2 Composition comprising cilobradine and a cardiostimulating agent, e.g. telmisartan |
| 06/07/2006 | EP1666041A2 Xanthine derivatives for treating neurodegenerative disorders |
| 06/07/2006 | EP1666038A1 Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1664798A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/07/2006 | EP1664769A2 Assay for detecting atrial and brain natriuretic peptide prohormones |
| 06/07/2006 | EP1664089A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof |
| 06/07/2006 | EP1664047A1 Substituted indolizine 1,2,3,6,7,8 derivatives, fgfs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives |
| 06/07/2006 | EP1663972A1 The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders |
| 06/07/2006 | EP1663339A1 Endoluminal prosthesis comprising a therapeutic agent |
| 06/07/2006 | EP1663310A1 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |